Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:APTX

Aptinyx (APTX) Stock Price, News & Analysis

Aptinyx logo

About Aptinyx Stock (NASDAQ:APTX)

Advanced Chart

Key Stats

Today's Range
$0.09
$0.10
50-Day Range
$0.06
$0.10
52-Week Range
$0.01
$0.72
Volume
231,126 shs
Average Volume
1.32 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

APTX Stock News Headlines

Apple Watch X: All the Rumors So Far
Trump Quietly Planning $15 Trillion Crypto Shocker
Most investors are still unaware, but I believe a new White House action may have quietly opened the floodgates for a $15 trillion crypto surge. My latest crypto playbook reveals the coin I’m most bullish on—including the name, ticker, and why I’m investing personal capital into it.
Patrick J Heron's Net Worth
Best Noise-Canceling Headphones for 2024
Aptinyx Inc APTX
See More Headlines

APTX Stock Analysis - Frequently Asked Questions

Aptinyx Inc. (NASDAQ:APTX) issued its earnings results on Tuesday, November, 9th. The company reported ($0.31) EPS for the quarter, meeting analysts' consensus estimates of ($0.31).

Aptinyx (APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aptinyx investors own include Plug Power (PLUG), Tesla (TSLA), Evofem Biosciences (EVFM), VBI Vaccines (VBIV), SCYNEXIS (SCYX), T2 Biosystems (TTOO) and ADMA Biologics (ADMA).

Company Calendar

Last Earnings
11/09/2021
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APTX
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1 million
Price / Cash Flow
N/A
Book Value
$0.57 per share
Price / Book
0.17

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.27
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:APTX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners